TELA Bio announced a strategic cost reduction initiative to preserve capital and extend its cash runway into 2028. The company is reducing its workforce by approximately 20%, from 201 to 160 full-time employees, aiming to lower annual operating expenses by $17.0 million. This restructuring involves a one-time charge of approximately $1.5 million for severance and related costs, expected to be substantially completed in the third quarter of 2026. Concurrently, Roberto Cuca stepped down as Chief Financial Officer and Chief Operating Officer effective August 31, 2026, due to termination without cause under his employment agreement. Heather Getz was appointed as the new principal financial officer. TELA Bio operates in the medical technology industry, providing soft-tissue reconstruction solutions.

TELA Bio, Inc. filed an amendment to disclose the separation agreement with former CEO Antony Koblish, effective August 7, 2026. Mr. Koblish ceased serving as CEO on August 3, 2026. Under the agreement, he receives twelve months of base salary paid ratably over one year and twelve months of COBRA premium coverage. All his equity awards immediately accelerate and vest upon the effective date. Performance stock units remain eligible to vest based on revenue and gross margin goals achieved by December 31, 2026, or at target if a change in control occurs before that date. The option exercise period is extended until December 31, 2027. TELA Bio operates in the biotechnology industry, developing medical devices for wound care.

TELA Bio reported second quarter 2026 revenue of $19.3 million, a 4% decline from the prior year period, driven by lower OviTex PRS volumes and price headwinds despite international growth of 26%. The company announced the appointment of Heather Getz as Chief Executive Officer effective August 4, 2026. Consequently, TELA Bio withdrew its full-year 2026 revenue guidance to reassess strategic direction while implementing cost reductions to extend cash runway. Cash and equivalents stood at $30.4 million on June 30, 2026. The company operates in the medical technology industry, providing soft-tissue reconstruction solutions.

TELA Bio, Inc. announced the departure of Antony Koblish as Chief Executive Officer and Director, effective August 3, 2026. The Board appointed Heather Getz as the new CEO and a Class II director on the same date. Getz’s employment agreement includes an annual base salary of $650,000 and a target bonus of 100% of her salary. She received initial equity inducement grants consisting of 1,365,000 standard options, 1,005,000 premium-priced options, and 500,000 restricted stock units. The filing notes that Koblish’s resignation was not due to disagreements regarding operations or policies. TELA Bio operates in the medical device industry, specializing in wound care solutions.

At its 2026 Annual Meeting of Stockholders held on June 9, 2026, TELA Bio, Inc. stockholders approved an amendment to the company's Amended and Restated 2019 Equity Incentive Plan. This amendment increases the authorized shares issuable under the plan by 3,500,000 shares. Additionally, Joseph Capper, Betty Jo Rocchio, and William Plovanic were elected as Class I directors, and the appointment of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year was ratified. Stockholders also provided non-binding advisory approval for executive compensation. TELA Bio, Inc. is a biotechnology company focused on regenerative medicine.